NVAX
Novavax, Inc.
NVAX's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NVAX overall, supported by stronger fundamentals.
NVAX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
NVAX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVAX PE Valuation
NVAX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 116x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NVAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NVAX to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NVAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.29 | -115% |
| Q2 2026 | -$1.35 | -157% |
| Q1 2026 | -$0.41 | -115% |
| Q4 2025 | $2.58 | +$3.81 |
| Q3 2025 | $1.89 | +$4.03 |
| Q2 2025 | $2.38 | +$5.02 |
| Q1 2025 | $2.75 | +$5.80 |
| Q4 2024 | -$1.23 | +$4.18 |
NVAX has swung to a loss: it lost $0.29 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NVAX on earnings quality, reporting a profit while its opponent remains loss making.
NVAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $68.3M | -3% |
| Q2 2026 | $56.7M | -76% |
| Q1 2026 | $139.5M | -79% |
| Q4 2025 | $147.1M | +67% |
| Q3 2025 | $70.4M | -17% |
| Q2 2025 | $239.2M | -42% |
| Q1 2025 | $666.7M | +610% |
| Q4 2024 | $88.3M | -70% |
NVAX's revenue has slid since its 2022 peak: $68M last quarter, down 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -46% | +207 points |
| Q2 2026 | -97% | -139 points |
| Q1 2026 | -11% | -88 points |
| Q4 2025 | 9.7% | +158 points |
| Q3 2025 | -253% | -94 points |
| Q2 2025 | 42% | +3.5 points |
| Q1 2025 | 77% | +232 points |
| Q4 2024 | -148% | -85 points |
NVAX's operating margin was −46% last quarter, up 207 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NVAX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NVAX on profitability, with a higher operating margin.
NVAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$95.3M | -190% |
| Q2 2026 | -$73.4M | +$54.3M |
| Q1 2026 | -$33.7M | +$153M |
| Q4 2025 | -$41.6M | +$133.5M |
| Q3 2025 | $105.8M | +$252M |
| Q2 2025 | -$127.7M | -141% |
| Q1 2025 | -$186.7M | -$96.3M |
| Q4 2024 | -$175.1M | +$10.5M |
NVAX has burned cash in most quarters: −$244M over the past year, against −$384M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NVAX on cash generation, producing positive trailing cash flow while its opponent burns cash.
NVAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +350K shares |
| 1 year | +1.6% | +2.6M shares |
| 3 years | +58% | +60.9M shares |
| 5 years | +123% | +90.8M shares |
| Available history | +584% | +141M shares |
NVAX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVAX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
NVAX's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NVAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.4 | Neutral |
| Stochastic | 41.0 | Neutral |
NVAX's weekly RSI is 46 (neutral) and its Stochastic is 41 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NVAX PE vs Healthcare Sector
| Metric | NVAX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NVAX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 17% below |
| 20 week MA | $9.52 | 8% below |
| 50 week MA | $8.98 | 2.4% below |
| 100 week MA | $8.32 | 5.3% above |
| 200 week MA | $8.39 | 4.4% above |
NVAX has slipped below its 8-, 20- and 50-week averages, though it's still 4.4% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NVAX on trend strength, trading above more of its moving averages.
NVAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.99 | $129.3 | +3142% |
| 2021 | $129.3 | $177.3 | +37% |
| 2022 | $177.3 | $9.66 | -95% |
| 2023 | $9.66 | $4.80 | -50% |
| 2024 | $4.80 | $8.28 | +72% |
| 2025 | $8.28 | $6.83 | -18% |
| 2026 YTD | $6.83 | $8.76 | +28% |
NVAX's yearly returns have swung widely, from +3142% in 2020 to −95% in 2022. It's up 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NVAX on returns for 2026, with the stronger performance.